Neurizon Initiates Pharmacokinetic Studies to Resolve FDA Clinical Hold on ALS Drug NUZ-001
Key Insights
Neurizon Therapeutics has submitted a formal request to the FDA detailing two short-term pharmacokinetic studies necessary to lift the clinical hold on NUZ-001, its investigational ALS (search) treatment.
The company will proactively commence the four-month studies in the coming weeks to generate additional animal exposure data specifically requested by the FDA.
The initiative, costing AUD$400,000 to AUD$600,000, aims to facilitate NUZ-001's entry into the HEALEY ALS (search) Platform Trial during the second half of 2025.
Neurizon Therapeutics Limited (search) has announced its decision to proactively initiate two pharmacokinetic studies aimed at resolving the FDA clinical hold on its investigational ALS (search) drug NUZ-001. The clinical-stage biotechnology company submitted a formal request for advice to the FDA detailing the studies necessary to lift the clinical hold, with the regulator expected to provide a formal response within 60 days.
FDA Engagement and Study Requirements
The company has been in ongoing communication with the FDA to seek clarification on requirements for lifting the clinical hold on NUZ-001, which was initially announced on February 17, 2025. The FDA specifically requested additional animal exposure data to assess the adequacy of systemic exposure to NUZ-001.
The two pharmacokinetic studies are designed to provide this additional animal exposure data and are expected to take approximately four months from commencement to completion. This timeline includes study start-up, a 28-day study treatment period, data analysis, and reporting. The initiative is expected to cost between AUD$400,000 to AUD$600,000 and is anticipated to be eligible for rebate under the Australian Government's Research and Development Tax Incentive Scheme.
Strategic Decision and Timeline
Managing Director and Chief Executive Officer Dr. Michael Thurn explained the rationale behind the proactive approach: "The decision to undertake two pharmacokinetic studies follows the ongoing review of our correspondences with the FDA to date, as well as close consultation with the Company's scientific and regulatory advisors. The two studies, which are anticipated to be completed in around four months, are expected to generate additional animal exposure data in line with the FDA's straightforward request to date to lift the clinical hold."
The decision to commence studies prior to receiving the FDA's formal response follows extensive engagement between the Board, management, and the company's scientific and regulatory advisors. Dr. Thurn emphasized that "undertaking these studies prior to the receipt of a formal response from the FDA highlights the Company's proactive approach to satisfying the regulator's request and our ongoing commitment to advancing NUZ-001 as an effective potential treatment for ALS (search) and other neurodegenerative diseases (search)."
Clinical Development Pathway
The timely execution of these studies is designed to enable NUZ-001's entry into the HEALEY ALS (search) Platform Trial during the second half of 2025. The additional pharmacokinetic data generated from these studies will also support the ongoing clinical development of NUZ-001 and future regulatory approval applications beyond the immediate need to lift the clinical hold.
About NUZ-001 and ALS Treatment
Neurizon is developing NUZ-001 for the treatment of ALS (search), which is described as the most common form of motor neurone disease (search). The company's strategy focuses on accelerating access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon aims to create new treatment horizons for patients and families impacted by complex neural disorders.